Joseph Joyce

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys
    Jiang Fan
    Department of Vaccine and Biologics Research, Merck Research Laboratories, 770 Sumneytown Pike, P.O. Box 4, WP16-306, West Point, PA 19486, USA
    Vaccine 22:2993-3003. 2004
  2. ncbi Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy
    Joseph Joyce
    Department of Vaccine and Biologics Research, Laboratory of Science and Investigative Toxicology and Bioprocess and Bioanalytical Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Biol Chem 281:4831-43. 2006
  3. ncbi Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41
    Donna L Montgomery
    Department of Biologics Research, Merck Research Laboratories, West Point, PA, USA
    MAbs 1:462-74. 2009
  4. ncbi Staphylococcus aureus capsule type 8 antibodies provide inconsistent efficacy in murine models of staphylococcal infection
    James Cook
    Merck Research Labs, Merck and Co, Inc, West Point, PA 19486, USA
    Hum Vaccin 5:254-63. 2009
  5. ncbi A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope
    Michael D Miller
    Department of Antiviral Research, Merck Research Laboratories, West Point, PA 19486, USA
    Proc Natl Acad Sci U S A 102:14759-64. 2005
  6. ncbi Antigen burden is major determinant of human immunodeficiency virus-specific CD8+ T cell maturation state: potential implications for therapeutic immunization
    Lynda G Tussey
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Infect Dis 187:364-74. 2003
  7. ncbi Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay
    David Opalka
    Vaccine and Biologics Research, Merck Research Laboratories, WYN-2, MRL-Wayne, 466 Devon Park Drive, Wayne, PA 19087-8630, USA
    J Immunol Methods 287:49-65. 2004
  8. ncbi Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide
    Tomas Maira-Litran
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Infect Immun 70:4433-40. 2002

Collaborators

Detail Information

Publications8

  1. ncbi Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys
    Jiang Fan
    Department of Vaccine and Biologics Research, Merck Research Laboratories, 770 Sumneytown Pike, P.O. Box 4, WP16-306, West Point, PA 19486, USA
    Vaccine 22:2993-3003. 2004
    ..The data presented here will permit better understanding of the potential of an M2-based vaccine approach...
  2. ncbi Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy
    Joseph Joyce
    Department of Vaccine and Biologics Research, Laboratory of Science and Investigative Toxicology and Bioprocess and Bioanalytical Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Biol Chem 281:4831-43. 2006
    ..The data suggested that for vaccine development, maintenance of the high mass of the polymer may be important...
  3. ncbi Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41
    Donna L Montgomery
    Department of Biologics Research, Merck Research Laboratories, West Point, PA, USA
    MAbs 1:462-74. 2009
    ....
  4. ncbi Staphylococcus aureus capsule type 8 antibodies provide inconsistent efficacy in murine models of staphylococcal infection
    James Cook
    Merck Research Labs, Merck and Co, Inc, West Point, PA 19486, USA
    Hum Vaccin 5:254-63. 2009
    ..aureus Becker obtained from in vivo growth conditions. These results indicated that functional capsule antibodies may not be sufficient for protection from S. aureus under all in vivo conditions...
  5. ncbi A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope
    Michael D Miller
    Department of Antiviral Research, Merck Research Laboratories, West Point, PA 19486, USA
    Proc Natl Acad Sci U S A 102:14759-64. 2005
    ..Our data provide a structural framework for the design of new immunogens and therapeutic antibodies with crossneutralizing potential...
  6. ncbi Antigen burden is major determinant of human immunodeficiency virus-specific CD8+ T cell maturation state: potential implications for therapeutic immunization
    Lynda G Tussey
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Infect Dis 187:364-74. 2003
    ..Such assessments of the immune response may provide a refined measure of virus control...
  7. ncbi Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay
    David Opalka
    Vaccine and Biologics Research, Merck Research Laboratories, WYN-2, MRL-Wayne, 466 Devon Park Drive, Wayne, PA 19087-8630, USA
    J Immunol Methods 287:49-65. 2004
    ..These evaluations demonstrated the substantial potential of the multiplexed antibody binding and mapping assay for rapid and sensitive analysis of complex antibody responses...
  8. ncbi Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide
    Tomas Maira-Litran
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Infect Immun 70:4433-40. 2002
    ..These results further clarify the chemical structure of PS/A and help to differentiate it from PIA on the basis of immunogenicity, molecular size, and solubility...